BillionToOne (BLLN)
Financials 
Technical Analysis 
Jul 2, 2026, 12:00 amThis summary was created by AI, based on 1 opinions in the last 12 months.
BillionToOne (BLLN-Q) has made a remarkable impact in the genetic testing industry, particularly with their ability to detect diseases early through advanced technology that surpasses competitors. The company has demonstrated impressive financial performance since its IPO, with a remarkable growth rate of 167% compounded annually since 2021 and significant revenue increases in the last year, including a 113% rise and projected growth of 112-120% in Q3. Notably, EBITDA turned positive recently, showcasing the company’s transition towards profitability. Despite these positive indicators and a clean balance sheet, experts note recent stock volatility and suggest that they are waiting for a further price pullback to enhance the stock’s attractiveness for investment.
- «
- ‹
- 1
- ›
- »
Popular Articles
Most Recent Experts
BillionToOne (BLLN) Frequently Asked Questions
What is BillionToOne stock symbol?
BillionToOne is a OTC stock, trading under the symbol BLLN (previously BLLN-Q on Stockchase) on the undefined (undefined). It is usually referred to as or BLLN
Is BillionToOne a buy or a sell?
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on BLLN (previously BLLN-Q on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is PARTIAL BUY. Read the latest stock experts' ratings for BillionToOne.
Is BillionToOne a good investment or a top pick?
BillionToOne was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for BillionToOne.
Why is BillionToOne stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for BillionToOne.
Is BillionToOne worth watching?
BillionToOne is covered by Stockchase experts and is worth watching.
They had an impressive IPO recently. They make genetic tests to detect diseases early. Their technology is superb and is ahead of their competition. Since 2021, sales have been rising at 167% compounded annually. Last year saw 113% revenue growth. Q3 guidance declared revenue growth at 112-120%. EBITDA turned positive earlier this year. Excellent growth and profitable. Also, they have a clean balance sheet. However, the stock has already seen a pullback, so there's volatility. Wants to see shares fall further to make it more attractive.